Neovasc has filed a patent for a flow reducing implant designed to reduce blood flow in a blood vessel. The implant consists of a hollow element with a flow passage that includes sections of different diameters. The smaller diameter section is smaller than the cross section of the blood vessel. Some embodiments of the invention also include tabs that anchor parallel to the blood vessel wall. GlobalData’s report on Neovasc gives a 360-degree view of the company including its patenting strategy.
According to GlobalData’s company profile on Neovasc, prosthetic cardiac valves was a key innovation area identified from patents.
Flow reducing implant for blood vessel with varying diameter
A recently filed patent (Publication Number: US20230165586A1) describes a radially expandable implantable device designed to modify blood flow through a blood vessel and increase blood flow to a region of ischemia. The device consists of a narrowed section with inlet and outlet ends, connected to a flared section. The size and ratio of the narrowed section to the flared section are selected to generate a pressure differential across the device, promoting increased blood flow to the ischemic region.
The patent claims that the ratio of the cross-sectional area of the narrowed section to the cross-sectional area of the flared section is in the range of approximately 0.2 to approximately 0.9. Additionally, the inner diameter of the narrowed section is in the range of approximately 1 mm to approximately 10 mm, while the maximum inner diameter of the flared section is in the range of approximately 2 mm to approximately 30 mm. These dimensions are crucial in generating the necessary pressure differential to enhance blood flow to the region of ischemia.
The device may also be coated with a material that promotes tissue ingrowth, aiding in the integration of the implant with the surrounding tissue. Furthermore, the narrowed section of the device can be configured to decrease blood flow through the blood vessel, specifically in the case of a coronary sinus. This decrease in blood flow, along with the associated pressure differential across the device, is claimed to be sufficient to induce angiogenesis, the formation of new blood vessels.
The flared section of the device consists of a first portion and a second portion, with the diameter decreasing from the first portion to the narrowed section. Similarly, a second flared section may be connected to the outlet end of the narrowed section, with a first portion that increases in diameter from the outlet end to the second portion, which has a substantially constant diameter. These design features contribute to the overall functionality of the device.
The device also includes a plurality of apertures in both the flared section and the narrowed section. These apertures are configured to provide greater stiffness to the narrowed section compared to the flared section and allow the flared section to expand to a larger diameter. The diameter of the narrowed section is fixed by the configuration of the apertures, and the length of the apertures increases as a function of the distance from the center of the narrowed section.
Overall, this patent describes a radially expandable implantable device that can modify blood flow and increase blood flow to a region of ischemia. The device's design, dimensions, and features are carefully selected to generate the necessary pressure differential and promote tissue ingrowth, angiogenesis, and expansion.